Aletli Periton Diyalizi ve Sürekli Ayaktan Periton Diyalizi Hastalarında Gastroözofajiyal Reflü Hastalığının Değerlendirilmesi

Amaç: Bu çalışmada iki ayrı periton diyalizi uygulaması olan sürekli ayaktan periton diyalizi (SAPD) ve aletli periton diyalizinin (APD) gastroözofajiyal reflü hastalığı (GÖRH) insidansına ve ilişkili olduğu faktörlere etkisini değerlendirmeyi amaçladık. Yöntemler: Çalışmaya APD tedavisi uygulanan 17 hasta ve SAPD tedavisi uygulanan 34 hasta dahil edildi. Hastaların gastrointestinal sistem şikayetleri, özgeçmiş özellikleri ve kullandıkları ilaçlar yüz yüze görüşme yöntemiyle elde edildi. Anket formu, bireylerin sosyodemografik özelliklerini, GÖRH ile ilişkili olduğu düşünülen bazı faktörler ile ilgili soruları içermekteydi. GÖRH değerlendirilmesinde National Institutes of Health PROMIS GERD Ölçeği kullanıldı. Bulgular: 51 hasta çalışmaya dahil edildi (31’i (%60.8) erkek, 20’si (%39.2) kadın). Hastaların yaşları 18-77 arasında değişmekte olup, ortalama 53±15 yıldı. Eğitim düzeyine göre hastaların 34’ü (%66.7) ilköğretim mezunu olup en büyük bölümü oluştururken, sadece 4’ü (%7.8) okuryazar değildi. Tüm hastalarda GÖRH sıklığı %31.4 oranında tespit edildi. GÖRH sıklığı APD uygulayan hastalarda %23.5, SAPD uygulayan hastalarda ise %35.3 olup, SAPD uygulayan hastalarda oran daha yüksekti, ancak aralarında istatistiksel olarak anlamlı fark yoktu (p= 0.594). GÖRH olanlarla olmayanlar arasında yaş, cinsiyet, rezidü renal fonksiyon varlığı, günlük ortalama PD sıvı miktarı ve ultrafiltrasyon miktarı açısından fark bulunmadı. Sonuç: Periton diyalizi hastalarında GÖRH sıklığı %31.4 olup, APD ve SAPD modalitelerinin GÖRH sıklığı üzerine etkisi benzer bulunmuştur.

Evaluation of Gastroesophageal Reflux Disease in Patients Treated with Automated Peritoneal Dialysis and Continuous Ambulatory Peritoneal Dialysis

Objective: In this study, we aimed to evaluate the effects of continuous ambulatory peritoneal dialysis (CAPD) and automated peritoneal dialysis (APD) on gastroesophageal reflux disease (GERD) and its associated factors. Methods: The study included 17 patients underwent APD and 34 patients took CAPD treatment. Face-to-face interview method was used to determine the patients' gastrointestinal system complaints, resume characteristics and medical therapies. The questionnaire included questions about the sociodemographic characteristics of individuals, some factors that were thought to be related to GERD. National Institutes of Health PROMIS GERD Scale was used for the evaluation of GERD. Results: Fifty-one patients [31(60.8%) male and 20(39.2%) female] were enrolled the study. Ages of the patients ranged from 18 to 77 years with a mean of 53±15 years. According to the level of education, 34 (66.7%) of the patients were primary school graduates and constituted the largest part, only 4 (7.8%) were illiterate. The incidence of GERD was 31.4% in all patients. The incidence of GERD was 23.5% in patients treated with APD and 35.3% in patients treated with CAPD. Although patients with CAPD had a higher GERD incidence, the difference was not statistically significant (p= 0.594). There was no statistically significant difference between the patients with and without GERD in terms of age, gender, presence of residual renal function, daily mean PD fluid amount, daily mean ultrafiltration amount. Conclusion: The incidence of GERD in patients with peritoneal dialysis was 31.4%, and the effect of APD and SAPD modalities on GERD frequency found similar. 

___

  • 1. El-Serag, H. B., Sweet, S., Winchester, C. C., & Dent, J.. Up¬date on the epidemiology of gastro-esophageal reflux disease: Asystematic review. Gut, 2014;63(6):871–80.
  • 2. Woolard, S., & Christie, J.. Gastroesophageal reflux disease. In S. Srinivasan, & L. Friedman (Eds.), Essentials of gastroenter¬ology (2nd ed., pp. 3–17). Hoboken, NJ: John Wiley & Sons Ltd. 2018.
  • 3. Katz, P., Gerson, L., & Vela, M.. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology, 2013;108:308–328.
  • 4. Cano AE, Neil AK, Kang JY, Barnabas A, Eastwood JB, et al. Gastrointestinal symptoms in patients with end-stage renal disease undergoing treatment by hemodialysis or peritoneal dialysis. Am J Gastroenterol 2007;102:1990-97.
  • 5. Anderson JE, Yim KB, Crowell MD. Prevalence of gastroesophageal reflux disease in peritoneal dialysis and hemodialysis patients. Adv Perit Dial. 1999;15:75-8.
  • 6. Song HJ, Kim SM, Lee YM, Hwang JA, Moon KM, et al. Is there a difference in the prevalence of gastroesophageal reflux disease between peritoneal dialysis and hemodialysis patients? Korean J Gastroenterol. 2013;62(4):206-12.
  • 7. Strid H, Simren M, Johansson AC, Svedlund J, Samuelsson O, et al. The prevalence of gastrointestinal symptoms in patients with chronic renal failure is increased and associated with impaired psychological general well-being. Nephrol Dial Transplant 2002;17:1434-39.
  • 8. Min F, Tarlo SM, Bargman J, Poonai N, Richardson R, et al. Prevalence and causes of cough in chronic dialysis patients: a comparison between hemodialysis and peritoneal dialysis patients. Adv Perit Dial 2000;16:129-33.
  • 9. Soykan I, Lin Z, Jones S, Chen J, McCallum RW. Gastric myoelectrical activity, gastric emptying and correlations with dyspepsia symptoms in patients with gastroesophageal reflux. J Investig Med 1997;45:483-7.
  • 10. Van Vlem B, Schoonjans RS, Struijk DG, Verbanck JJ, Vanholder RC, et al. Influence of dialysate on gastric emptying time in peritoneal dialysis patients. Perit Dial Int 2002;22:32-8.
  • 11. Spiegel BM, Hays RD, Bolus R, Melmed GY, Chang L, et al. Development of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol. 2014;109:1804-14.
  • 12. Özseker B, Yasar NF, Bilgin M, Kurt Y, Balcioglu H, et al. Turkish validation of National Institutes of Health (NIH) patient- reported outcomes measurement information system (PROMISÂŪ) Gastroesophageal Reflux Disease (GERD) scale. Biomedical Research. 2016;27:577-81.
  • 13. Oğuz D, Köksal AŞ, Özden A. The frequency of gastroesophageal reflux disease in patients to primary health care centers in Turkey. Akademik Gastroenteroloji Dergisi. 2008;7:137-43.
  • 14. Furukawa N, Iwakiri R, Koyama T, Okamoto K, Yoshida T, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol 1999;34: 441-4.
  • 15. Ala-Kaila K. Upper gastrointestinal findings in chronic renal failure. Scand J Gastroenterol 1987;22:372-6.
  • 16. Kawaguchi Y, Mine T, Kawana I, Yasuzaki H, Kokuho T, et al. Gastroesophageal Reflux Disease in Hemodialysis Patients. Tokai J Exp Clin Med. 2009;34(2):48-52.
  • 17. Kang JY. The gastrointestinal tract in uremia. Dig Dis Sci 1993;38(2):257-68.
  • 18. Shousha S, Arnaout AH, Abbas SH, Parkins RA. Antral Helicobacter pylori in patients with chronic renal failure. J Clin Pathol 1990;4(5):397-9.
  • 19. Strid H, Fjell A, Simrén M, Björnsson ES. Impact of dialysis on gastroesophageal reflux, dyspepsia, and proton pump inhibitor treatment in patients with chronic renal failure. Eur J Gastroenterol Hepatol 2009;21:137–42.
  • 20. Strid H, Simrén M, Stotzer PO, Abrahamsson H, Björnsson ES. Delay in gastric emptying in patients with chronic renal failure. Scand J Gastroenterol 2004;39:516-20.
  • 21. Hubalewska A, Stompór T, Płaczkiewicz E, Staszczak A, Huszno B, et al. Evaluation of gastric emptying in patients with chronic renal failure on continuous ambulatory peritoneal dialysis using 99mTc-solid meal. Nucl Med Rev Cent East Eur 2004;7:27–30.
  • 22. Fernström A, Hylander B, Grybäck P, Jacobsson H, Hellström PM. Gastric emptying and electrogastrography in patients on CAPD. Perit Dial Int 1999;19: 429-37.
  • 23. Horowitz M, Harding PE, Maddox AF, Wishart JM, Akkermans LM, , et al. Gastric and oesophageal emptying in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1989;32:151-9.
  • 24. Bjornsson ES, Urbanavicius V, Eliasson B, Attvall S, Smith U, et al. Effects of hyperglycemia on interdigestive gastrointestinal motility in humans. Scand J Gastroenterol 1994;29:1096-104.
  • 25. Dejardin A, Robert A, Goffin E. Intraperitoneal pressure in PD patients: relationship to intraperitoneal volume, body size and PD-related complications. Nephrol Dial Transplant 2007;22:1437-44.
  • 26. Hylander BI, Dalton CB, Castell DO, Burkart J, Rossner S. Effect of intraperitoneal fluid volume changes on esophageal pressures: studies in patients on continuous ambulatory peritoneal dialysis. Am J Kidney Dis 1991;17:307-10.
  • 27. Lee YC, Hung SY, Wang HH, Wang HK, Lin CW, et al. Different Risk of Common Gastrointestinal Disease Between Groups Undergoing Hemodialysis or Peritoneal Dialysis or With Non-End Stage Renal Disease: A Nationwide Population-Based Cohort Study. Medicine (Baltimore). 2015;94(36):e1482.
  • 28. Kim N, Lee SW, Cho SI, Park CG, Yang CH, et al. H. pylori and Gerd Study Group of Korean College of Helicobacter and Upper Gastrointestinal Research. The prevalence of and risk factors for erosive oesophagitis and non-erosive reflux disease: a nationwide multicentre prospective study in Korea. Aliment Pharmacol Ther 2008;27:173-185.
  • 29. Kim BC, Yoon YH, Jyung HS, Chung JB, Chon CY, et al. Clinical characteristics of gastroesophageal reflux diseases and association with Helicobacter pylori infection. Korean J Gastroenterol 2006;47:363-9.